These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7907646

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S, Gockel K, Horowitz S, Weber P, Vogelman B, Graziano F.
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
    Schwartländer B, Bek B, Skarabis H, Koch J, Burkowitz J, Koch MA.
    AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
    DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P.
    J Infect Dis; 1994 Apr; 169(4):713-21. PubMed ID: 8133085
    [Abstract] [Full Text] [Related]

  • 27. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR, Lizioli A, Arcidiacono I, Cantaluppi P, Filippi C, Sobatti D, Bedarida G, D'Agostino F, Cambie G, Nardella ML.
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [Abstract] [Full Text] [Related]

  • 28. The effect of immunodeficiency on cutaneous delayed-type hypersensitivity testing in HIV-infected women without anergy: implications for tuberculin testing. HER Study Group. HIV Epidemiology Research.
    Klein RS, Flanigan T, Schuman P, Smith D, Vlahov D.
    Int J Tuberc Lung Dis; 1999 Aug; 3(8):681-8. PubMed ID: 10460100
    [Abstract] [Full Text] [Related]

  • 29. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group.
    McKinney RE, Wilfert C.
    J Pediatr; 1994 Nov; 125(5 Pt 1):728-33. PubMed ID: 7965424
    [Abstract] [Full Text] [Related]

  • 30. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [Abstract] [Full Text] [Related]

  • 31. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T.
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [Abstract] [Full Text] [Related]

  • 32. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.
    Krämer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, Goedert JJ.
    Am J Epidemiol; 1992 Jul 01; 136(1):71-80. PubMed ID: 1384311
    [Abstract] [Full Text] [Related]

  • 33. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection.
    Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG.
    Ann Intern Med; 1990 Oct 01; 113(7):512-9. PubMed ID: 1975487
    [Abstract] [Full Text] [Related]

  • 34. Spontaneous in vitro anti-human immunodeficiency virus type 1 antibody secretion by peripheral blood mononuclear cells is related to disease progression in zidovudine-treated adults.
    Conge AM, Reynes J, Atoui N, Huguet MF, Ducos J, Bonardet A, Serre A, Vendrell JP.
    J Infect Dis; 1994 Dec 01; 170(6):1376-83. PubMed ID: 7995975
    [Abstract] [Full Text] [Related]

  • 35. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 36. Delayed hypersensitivity skin tests in prognosis of human immunodeficiency virus infection.
    Zeballos RS, Cavalcante N, Freire CA, Hernandez HJ, Longo IM, Peixinho ZF, Moura NC, Mendes NF.
    J Clin Lab Anal; 1992 Sep 11; 6(3):119-22. PubMed ID: 1354723
    [Abstract] [Full Text] [Related]

  • 37. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE.
    AIDS; 1992 Jul 11; 6(7):671-7. PubMed ID: 1503686
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS.
    Karlsson A, Moberg L, Bratt G, Halvarsson M, von Krogh G, Morfeldt L, Sandström E.
    Scand J Infect Dis; 1996 Jul 11; 28(2):125-30. PubMed ID: 8792477
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.